Gadd45a transcriptional induction elicited by the Aurora kinase inhibitor MK-0457 in Bcr-Abl-expressing cells is driven by Oct-1 transcription factor

Leukemia Research

Volumn 36, Issue 8, 2012, Pages 1028-1034

  Mancini, Manuela ^a   Leo, Elisa ^a   Aluigi, Michela ^a   Marcozzi, Chiara ^a   Borsi, Enrica ^a   Barbieri, Enza ^a   Santucci, Maria Alessandra ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

Bcr Abl; Chromatin epigenetic modifications; Chronic myeloid leukemia; G 2 M checkpoint; Gadd45a; Oct 1 transcription factor; Transcriptional regulation

Indexed keywords

AURORA A KINASE; AURORA B KINASE; BCR ABL PROTEIN; GROWTH ARREST AND DNA DAMAGE INDUCIBLE PROTEIN 45; GROWTH ARREST AND DNA DAMAGE INDUCIBLE PROTEIN 45A; HISTONE H3; OCTAMER TRANSCRIPTION FACTOR 1; TOZASERTIB; UNCLASSIFIED DRUG;

ANIMAL CELL; APOPTOSIS; ARTICLE; CELL CYCLE ARREST; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CELL CYCLE PROGRESSION; CELL POPULATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFICACY; DRUG MECHANISM; GENETIC TRANSCRIPTION; NONHUMAN; POLYPLOIDY; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN DEPHOSPHORYLATION; PROTEIN EXPRESSION; PROTEIN PROCESSING;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL CYCLE PROTEINS; CELLS, CULTURED; DRUG RESISTANCE, NEOPLASM; EPIGENESIS, GENETIC; FUSION PROTEINS, BCR-ABL; GENE EXPRESSION REGULATION, LEUKEMIC; HISTONES; HUMANS; K562 CELLS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MICE; NUCLEAR PROTEINS; OCTAMER TRANSCRIPTION FACTOR-1; PIPERAZINES; PROMOTER REGIONS, GENETIC; PROTEIN KINASE INHIBITORS; PROTEIN-SERINE-THREONINE KINASES; TRANSCRIPTIONAL ACTIVATION; UP-REGULATION;

EID: 84862581871     PISSN: 01452126     EISSN: 18735835     Source Type: Journal    
DOI: 10.1016/j.leukres.2012.03.025     Document Type: Article

References (47)

1. Liebermann D.A., Hoffman B. Gadd45 in stress signaling. J Mol Signal 2008, 3:15.
2. Barreto G., Schafer A., Marhold J., Stach D., Swaminathan S.K., Handa V., et al. Gadd45a promotes epigenetic gene activation by repair-mediated DNA demethylation. Nature 2007, 445:671-675.
3. Hollander M.C., Fornace A.J. Genomic instability, centrosome amplification, cell cycle checkpoints and Gadd45a. Oncogene 2002, 21:6228-6233.
4. Hollander M.C., Sheikh M.S., Bulavin D.V., Lundgren K., Augeri-Henmueller L., Shehee R., et al. Genomic instability in Gadd45a-deficient mice. Nat Genet 1999, 23:176-184.
5. Zerbini L.F., Libermann T.A. Gadd45 deregulation in cancer: frequently methylated tumor suppressors and potential therapeutic targets. Clin Cancer Res 2005, 11:6409-6413.
6. 2-terminal kinase and p38 stress signaling resulting in apoptosis and senescence. Cancer Res 2006, 66:8448-8454.
7. Shao S., Wang Y., Jin S., Song Y., Wang X., Fan W., et al. Gadd45a interacts with Aurora-A and inhibits its kinase activity. J Biol Chem 2006, 281:28943-28950.
8. Lens S.M.A., Voest E.E., Medema R.H. Shared and separate functions of polo-like kinases and Aurora kinases in cancer. Nat Rev Cancer 2010, 10:825-841.
9. Dutertre S., Descamps S., Prigent C. On the role of Aurora-A in centrosome function. Oncogene 2002, 21:6175-6183.
10. Burke B.A., Carroll M. BCR-ABL: a multi-faceted promoter of DNA mutation in chronic myelogenous leukemia. Leukemia 2010, 24:1105-1112.
11. Kim J.H., Chu S.C., Gramlich J.L., Pride Y.B., Babendreier E., Chauhan D., et al. Activation of the PI3K/mTOR pathway by BCR-ABL contributes to increased production of reactive oxygen species. Blood 2005, 105:1717-1723.
12. Penserga E.T., Skorski T. Fusion tyrosine kinases: a result and cause of genomic instability. Oncogene 2007, 26:11-20.
13. Naughton R., Quiney C., Turner S.D., Cotter T.G. Bcr-Abl-mediated redox regulation of the PI3K/AKT pathway. Leukemia 2009, 23:1432-1440.
14. Perrotti D., Jamieson C., Goldman J., Skorski T. Chronic myeloid leukemia: mechanisms of blastic transformation. J Clin Invest 2010, 120:2254-2264.
15. Wolanin K., Magalska A., Kusio-Kobialka M., Podszywalow-Bartnicka P., Vejda S., McKenna S.L., et al. Expression of oncogenic kinase Bcr-Abl impairs mitotic checkpoint and promotes aberrant division and resistance to microtubule-targeting agents. Mol Cancer Ther 2010, 9:1328-1338.
16. Moore A.S., Blagg J., Linardopoulos S., Pearson A.D. Aurora kinase inhibitors: novel small molecules with promising activity in acute myeloid and philadelphia-positive leukemias. Leukemia 2010, 24:671-678.
17. Young M.A., Shah N.P., Chao L.H., Seeliger M., Milanov Z.V., Biggs W.H., et al. Structure of the kinase domain of an imatinib-resistant Abl mutant in complex with the Aurora kinase inhibitor VX-680. Cancer Res 2006, 66:1007-1014.
18. Crosio C., Fimia G.M., Loury R., Kimura M., Okano Y., Zhou H., et al. Mitotic phosphorylation of histone H3: spatio-temporal regulation by mammalian Aurora kinases. Mol Cell Biol 2002, 22:874-885.
19. Kang T.J., Yuzawa S., Suga H. Expression of histone H3 tails with combinatorial lysine modifications under the reprogrammed genetic code for the investigation on epigenetic markers. Chem Biol 2008, 15:1166-1174.
20. Hirose T., Sowa Y., Takahashi S., Saito S., Yasuda C., Shindo N., et al. p53-independent induction of Gadd45 by histone deacetylase inhibitor: coordinate regulation by transcription factors Oct-1 and NF-Y. Oncogene 2003, 22:7762-7773.
21. Brusa G., Zuffa E., Mancini M., Benvenuti M., Calonghi N., Barbieri E., et al. P210 Bcr-Abl tyrosine kinase interaction with histone deacetylase 1 modifies histone H4 acetylation and chromatin structure of chronic myeloid leukaemia haematopoietic progenitors. Br J Haematol 2005, 132:359-369.
22. Santucci M.A., Ripalti A., Di Paola M.C., Mianulli A.M., Iacurti E., Campanini F., et al. Procedure for the quantitation of Gadd45 expression levels in clonal hematopoietic progenitor cells by competitive polymerase chain reaction. Clin Biochem 1999, 32:1-8.
23. Honda K., Mihara H., Kato Y., Yamaguchi A., Tanaka H., Yasuda H., et al. Degradation of human Aurora2 protein kinase by the anaphase-promoting complex-ubiquitin-proteasome pathway. Oncogene 2000, 19:2812-2819.
24. Chu S., McDonald T., Bhatia R. Role of BCR-ABL-Y177 mediated p27kip1 phosphorylation and cytoplasmatic localization in enhanced proliferation of chronic myeloid leukemia. Leukemia 2010, 24:779-787.
25. Jin S., Fan F., Fan W., Zhao H., Tong T., Blanck P., et al. Transcription factors Oct-1 and NF-YA regulate the p53-independent induction of Gadd45 following DNA damage. Oncogene 2001, 20:2683-2690.
26. Méndez-Acuna L., Di Tomaso M.V., Palitti F., Martinez-Lòpez W. Histone post-translational modifications in DNA damage response. Cytogenet Genome Res 2010, 128:28-36.
27. Donato N.J., Fang D., Sun H., Giannola D., Peterson L.F., Talpaz M. Targets and effectors of the cellular response to aurora kinase inhibitor MK-0457 (VX-680) in imatinib sensitive and resistant chronic myelogenous leukemia. Biochem Pharmacol 2010, 79:688-697.
28. Giles F.J., Cortes J., Jones D., Bergstrom D., Kantarjian H., Freedman S.J. MK-0457, a novel kinase inhibitor, is active in patients with chronic myeloid leukemia or acute lymphocytic leukemia with the T315I BCR-ABL mutation. Blood 2007, 109:500-502.
29. Gontarewicz A., Balabanov S., Keller G., Panse J., Schafhausen P., Bokemeyer C., et al. PHA-680626 exhibits anti-proliferative and pro-apoptotic activity on imatinib-resistant chronic myeloid leukemia cell lines and primary CD34+ cells by inhibition of both Bcr-Abl tyrosine kinase and Aurora kinases. Leuk Res 2008, 32:1857-1865.
30. Akahane D., Tauchi T., Okabe S., Nunoda K., Ohyashiki K. Activity of a novel Aurora kinase inhibitor against the T315I mutant form of BCR-ABL: in vitro and in vivo studies. Cancer Sci 2008, 99:1251-1257.
31. Gontarewicz A., Balabanov S., Keller G., Colombo R., Graziano A., Pesenti E., et al. Simultaneous targeting of Aurora kinases and Bcr-Abl kinase by the small molecule inhibitor PHA-739358 is effective against imatinib-resistant BCR-ABL mutations including T315I. Blood 2008, 111:4355-4364.
32. Okabe S., Tauchi T., Ohyashiki J.H., Ohyashiki K. Mechanisms of MK-0457 against BCR-ABL positive leukemia cells. Biochem Biophys Res Commun 2009, 380:775-779.
33. Kelly K.R., Ecsedy J., Medina E., Mahalingam D., Padmanabhan S., Nawrocki S.T., et al. The novel Aurora A kinase inhibitor MLN8237 is active in resistant chronic myeloid leukaemia and significantly increases the efficacy of nilotinib. J Cell Mol Med 2011, 15:2057-2070.
34. 2/M checkpoint. J Biol Chem 2000, 275:36892-36898.
35. Tyler R.K., Shpiro N., Marquez R., Eyers P.A. VX-680 inhibits Aurora A and B kinase activity in human cells. Cell Cycle 2007, 6:2846-2854.
36. Sànchez R., Pantoja-Uceda D., Prieto J., Diercks T., Marcaida M.J., Montoya G., et al. Solution structure of human growth arrest and DNA damage 45α (Gadd45α) and its interactions with proliferating cell nuclear antigen (PCNA) and Aurora A kinase. J Biol Chem 2010, 285:22196-22201.
37. Kastan M.B., Zhan Q., el-Deiry W.S., Carrier F., Jacks T., Walsh W.W., et al. A mammalian cell cycle checkpoint pathway utilizing p53 and Gadd45 is defective in ataxia-telengectasia. Cell 1992, 71:587-597.
38. Takahashi S., Saito S., Ohtani N., Sakai T. Involvement of the Oct-1 regulatory element of Gadd45 promoter in the p53-independent response to ultaviolet irradiation. Cancer Res 2001, 61:1187-1195.
39. Khorasanizadeh S. The nucleosome: from genomic organization to genomic regulation. Cell 2004, 116:259-272.
40. Dormann H.L., Tseng B.S., Allis C.D., Funabiki H., Fischle W. Dynamic regulation of effector protein binding to histone modifications: the biology of HP1 switching. Cell Cycle 2006, 5:2842-2851.
41. San José-Eneriz E., Agirre X., Jiménez-Velasco A., Cordeu L., Martin V., Arqueros V., et al. Epigenetic down-regulation of BIM expression is associated with reduced optimal response to imatinib treatment in chronic myeloid leukemia. Eur J Cancer 2009, 45:1877-1889.
42. Schild-Poulter C., Shih A., Tantin D., Yarymowich N.C., Soubeyrand S., Sharp P.A., et al. DNA-PK phosphorylation sites in Oct-1 promote cell survival following DNA damage. Oncogene 2007, 26:3980-3988.
43. Deutsch E., Dugray A., AdbulKarim B., Marangoni E., Maggiorella L., Vaganay S., et al. BCR-ABL down-regulates the DNA repair protein DNA-PKcs. Blood 2001, 97:2084-2090.
44. Ma D.K., Guo J.U., Ming G., Song H. DNA excision repair proteins and Gadd45 as molecular players for active DNA demethylation. Cell Cycle 2009, 8:1526-1531.
45. Zerbini L.F., Wang Y., Czibere A., Correa R.G., Cho J.Y., Ijiri K., et al. NF-kappa B-mediated repression of growth arrest- and DNA-damage-inducible proteins 45alpha and gamma is essential for cancer cell survival. Proc Natl Acad Sci USA 2004, 101:13618-13623.
46. Fabbro M., Henderson B.R. BARD1 regulates BRCA1-mediated transactivation of the p21WAF1/CIP1 and Gadd45 promoters. Cancer Lett 2008, 18:189-196.
47. Amente S., Zhang J., Lavadera M., Lania L., Avvedimento E.V., Majello B. Myc and PI3K/AKT signaling coperatively represses FOXO3a-dependent PUMA and Gadd45a gene expression. Nucleic Acids Res 2011, [Epub ahead of print].